{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T05:10:08Z","timestamp":1752124208302,"version":"3.41.2"},"reference-count":151,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>The intricate anatomical and physiological barriers that prohibit pharmaceuticals from\nentering the brain continue to provide a noteworthy hurdle to the efficient distribution of medications\nto brain tissues. These barriers prevent the movement of active therapeutic agents into the\nbrain. The present manuscript aims to describe the various aspects of brain-targeted drug delivery\nthrough the nasal route. The primary transport mechanism for drug absorption from the nose to\nthe brain is the paracellular\/extracellular mechanism, which allows for rapid drug transfer. The\ntranscellular\/intracellular pathway involves the transfer across a lipoidal channel, which regulates\nthe entry or exit of anions, organic cations, and peptides. Spectroscopy and PET (positron emission\ntomography) are two common methods used for assessing drug distribution. MRI (Magnetic\nresonance imaging) is another imaging method used to assess the efficacy of aerosol drug delivery\nfrom nose to brain. It can identify emphysema, drug-induced harm, mucus discharge, oedema, and\nvascular remodeling. The olfactory epithelium's position in the nasal cavity makes it difficult for\ndrugs to reach the desired target. Bi-directional aerosol systems and tools like the \u201cOptiNose\u201d can\nhelp decrease extranasal particle deposition and increase particle deposition efficiency in the primary\nnasal pathway. Direct medicine administration from N-T-B, however, can reduce the dose\nadministered and make it easier to attain an effective concentration at the site of activity, and it\nhas the potential to be commercialized.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115672018285350240227073607","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T11:51:25Z","timestamp":1713009085000},"page":"678-693","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Aerosol Formulation for Targeted Delivery of Therapeutic Agents from Nose to Brain"],"prefix":"10.2174","volume":"22","author":[{"given":"Shristy","family":"Verma","sequence":"first","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod Kumar","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2874-6149","authenticated-orcid":true,"given":"Rishabha","family":"Malviya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.addr.2007.11.006","volume":"60","author":"Azarmi S.","year":"2008","unstructured":"Azarmi S.; Roa W.H.; L\u00f6benberg R.; Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev  2008,60(8),863-875","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ejpb.2006.10.021","volume":"65","author":"Ely L.","year":"2007","unstructured":"Ely L.; Roa W.; Finlay W.H.; L\u00f6benberg R.; Effervescent dry powder for respiratory drug delivery. Eur J Pharm Biopharm  2007,65(3),346-353","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.rmr.2014.06.032","volume":"32","author":"Benattia A.","year":"2015","unstructured":"Benattia A.; Cavaillon P.; Gachelin E.; Devillier P.; Vecellio L.; Williams G.; Dubus J.C.; Inhaled treatments: Device selection criteria, systemic absorption of inhaled drugs and pulmonary bitterness receptors. Rev Mal Respir  2015,32(8),791-799","journal-title":"Rev Mal Respir"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJM198610023151406","volume":"315","author":"Newhouse M.T.","year":"1986","unstructured":"Newhouse M.T.; Dolovich M.B.; Control of asthma by aerosols. N Engl J Med  1986,315(14),870-874","journal-title":"N Engl J Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1089\/jam.2006.19.36","volume":"19","author":"Smaldone G.C.","year":"2006","unstructured":"Smaldone G.C.; Advances in aerosols: Adult respiratory disease. J Aerosol Med  2006,19(1),36-46","journal-title":"J Aerosol Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1513\/pats.200409-046TA","volume":"1","author":"Heyder J.","year":"2004","unstructured":"Heyder J.; Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc  2004,1(4),315-320","journal-title":"Proc Am Thorac Soc"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/10717549709051878","volume":"4","author":"Frey W.H.","year":"1997","unstructured":"Frey W.H.; Liu J.; Chen X.; Thorne R.G.; Fawcett J.R.; Ala T.A.; Rahman Y.E.; Delivery of  I-NGF to the brain via the olfactory route. Drug Deliv  1997,4(2),87-92","journal-title":"Drug Deliv"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1021\/acs.molpharmaceut.5b00088","volume":"12","author":"Mistry A.","year":"2015","unstructured":"Mistry A.; Stolnik S.; Illum L.; Nose-to-brain delivery: Investigation of the transport of nanoparticles with different surface characteristics and sizes in excised porcine olfactory epithelium. Mol Pharm  2015,12(8),2755-2766","journal-title":"Mol Pharm"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jconrel.2018.10.004","volume":"291","author":"Khan A.R.","year":"2018","unstructured":"Khan A.R.; Yang X.; Fu M.; Zhai G.; Recent progress of drug nanoformulations targeting to brain. J Control Release  2018,291,37-64","journal-title":"J Control Release"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","volume":"87","author":"Illum L.","year":"2003","unstructured":"Illum L.; Nasal drug delivery\u2014Possibilities, problems and solutions. J Control Release  2003,87(1-3),187-198","journal-title":"J Control Release"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/pharmaceutics11020084","volume":"11","author":"Bonferoni M.","year":"2019","unstructured":"Bonferoni M.; Rossi S.; Sandri G.; Ferrari F.; Gavini E.; Rassu G.; Giunchedi P.; Nanoemulsions for \u201cnose-to-brain\u201d drug delivery. Pharmaceutics  2019,11(2),84","journal-title":"Pharmaceutics"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11060-013-1346-5","volume":"116","author":"Peterson A.","year":"2014","unstructured":"Peterson A.; Bansal A.; Hofman F.; Chen T.C.; Zada G.; A systematic review of inhaled intranasal therapy for central nervous system neoplasms: An emerging therapeutic option. J Neurooncol  2014,116(3),437-446","journal-title":"J Neurooncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","volume":"143","author":"Erd\u0151 F.","year":"2018","unstructured":"Erd\u0151 F.; Bors L.A.; Farkas D.; Bajza \u00c1.; Gizurarson S.; Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull  2018,143,155-170","journal-title":"Brain Res Bull"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.5772\/65245","author":"Maiti S.","year":"2017","unstructured":"Maiti S.; Sen K.K.; Introductory chapter: Drug delivery concepts. Advanced Technology for Delivering Therapeutics  2017","journal-title":"Advanced Technology for Delivering Therapeutics"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.neuropharm.2011.08.016","volume":"62","author":"Lukas M.","year":"2012","unstructured":"Lukas M.; Neumann I.D.; Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: Social versus non-social effects. Neuropharmacology  2012,62(1),398-405","journal-title":"Neuropharmacology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"Craft S.","year":"2012","unstructured":"Craft S.; Baker L.D.; Montine T.J.; Minoshima S.; Watson G.S.; Claxton A.; Arbuckle M.; Callaghan M.; Tsai E.; Plymate S.R.; Green P.S.; Leverenz J.; Cross D.; Gerton B.; Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol  2012,69(1),29-38","journal-title":"Arch Neurol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"120474","DOI":"10.1016\/j.ijpharm.2021.120474","volume":"600","author":"Patel H.P.","year":"2021","unstructured":"Patel H.P.; Chaudhari P.S.; Gandhi P.A.; Desai B.V.; Desai D.T.; Dedhiya P.P.; Vyas B.A.; Maulvi F.A.; Nose to brain delivery of tailored clozapine nanosuspension stabilized using (+)-alpha-tocopherol polyethylene glycol 1000 succinate: Optimization and in vivo pharmacokinetic studies. Int J Pharm  2021,600,120474","journal-title":"Int J Pharm"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/jps.20480","volume":"95","author":"Vyas T.K.","year":"2006","unstructured":"Vyas T.K.; Babbar A.K.; Sharma R.K.; Singh S.; Misra A.; Intranasal mucoadhesive microemulsions of clonazepam: Preliminary studies on brain targeting. J Pharm Sci  2006,95(3),570-580","journal-title":"J Pharm Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"E49","DOI":"10.1208\/pt070108","volume":"7","author":"Vyas T.K.","year":"2006","unstructured":"Vyas T.K.; Babbar A.K.; Sharma R.K.; Singh S.; Misra A.; Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech  2006,7(1),E49-E57","journal-title":"AAPS PharmSciTech"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3109\/1061186X.2011.558090","volume":"19","author":"Jayachandra Babu R.","year":"2011","unstructured":"Jayachandra Babu R.; Dayal P.P.; Pawar K.; Singh M.; Nose- to-brain transport of melatonin from polymer gel suspensions: A microdialysis study in rats. J Drug Target  2011,19(9),731-740","journal-title":"J Drug Target"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40005-022-00589-5","volume":"53","author":"Jeong S.H.","year":"2023","unstructured":"Jeong S.H.; Jang J.H.; Lee Y.B.; Drug delivery to the brain via the nasal route of administration: Exploration of key targets and major consideration factors. J Pharm Investig  2023,53(1),119-152","journal-title":"J Pharm Investig"},{"key":"ref=22","first-page":"331","volume":"8","author":"Wearley L.L.","year":"1991","unstructured":"Wearley L.L.; Recent progress in protein and peptide delivery by noninvasive routes. Crit Rev Ther Drug Carrier Syst  1991,8(4),331-394","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0022-510X(01)00532-9","volume":"187","author":"Liu X.F.","year":"2001","unstructured":"Liu X.F.; Fawcett J.R.; Thorne R.G.; DeFor T.A.; Frey W.H.; Intranasal administration of insulin-like growth factor-I bypasses the blood\u2013brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci  2001,187(1-2),91-97","journal-title":"J Neurol Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ejcb.2009.02.001","volume":"88","author":"Danielyan L.","year":"2009","unstructured":"Danielyan L.; Sch\u00e4fer R.; von Mayerhofer A.A.; Buadze M.; Geisler J.; Klopfer T.; Burkhardt U.; Proksch B.; Verleysdonk S.; Ayturan M.; Buniatian G.H.; Gleiter C.H.; Frey W.H.; Intranasal delivery of cells to the brain. Eur J Cell Biol  2009,88(6),315-324","journal-title":"Eur J Cell Biol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4236\/jct.2011.21003","volume":"2","author":"Fonseca C.O.D.","year":"2011","unstructured":"Fonseca C.O.D.; Teixeira R.M.; Ramina R.; Kovaleski G.; Silva J.T.; Nagel J.; Quirico-Santos T.; Case of advanced recurrent glioblastoma successfully treated with monoterpene perillyl alcohol by intranasal administration. J Cancer Ther  2011,2(1),16-21","journal-title":"J Cancer Ther"},{"key":"ref=26","first-page":"44","volume":"20","author":"Patil J.","year":"2012","unstructured":"Patil J.; Sarasija S.;  Pulmonary drug delivery strategies: A concise, systematic review. Lung India  2012,20(1),44-49","journal-title":"Lung India"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v19.i45.40","volume":"19","author":"Courrier H.","year":"2002","unstructured":"Courrier H.; Butz N.; Vandamme T.F.; Pulmonary drug delivery systems: Recent developments and prospects. Crit Rev Ther Drug Carrier Syst  2002,19(4-5),425-498","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2174\/1566524013363384","volume":"1","author":"Palecanda G.","year":"2001","unstructured":"Palecanda G.; Kobzik L.; Receptors for unopsonized particles: The role of alveolar macrophage scavenger receptors. Curr Mol Med  2001,1(5),589-595","journal-title":"Curr Mol Med"},{"key":"ref=29","first-page":"6","volume":"37","author":"Agarwal V.","year":"1999","unstructured":"Agarwal V.; Mishra B.; Recent trends in drug delivery systems: Intranasal drug delivery. Indian J Exp Biol  1999,37(1),6-16","journal-title":"Indian J Exp Biol"},{"key":"ref=30","first-page":"1","volume":"2","author":"Aurora J.","year":"2002","unstructured":"Aurora J.; Development of nasal delivery systems: A review. Drug Deliv Technol  2002,2(7),1-8","journal-title":"Drug Deliv Technol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1742-1241.1997.tb11466.x","volume":"51","author":"Jones N.S.","year":"1997","unstructured":"Jones N.S.; Quraishi S.; Mason J.D.T.; The nasal delivery of systemic drugs. Int J Clin Pract  1997,51(5),308-311","journal-title":"Int J Clin Pract"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0169-409X(97)00063-X","volume":"29","author":"Behl C.R.","year":"1998","unstructured":"Behl C.R.; Pimplaskar H.K.; Sileno A.P.; deMeireles J.; Romeo V.D.; Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev  1998,29(1-2),89-116","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=33","first-page":"140","volume":"36","author":"Talegaonkar S.","year":"2004","unstructured":"Talegaonkar S.; Mishra P.R.; Intranasal delivery: An approach to bypass the blood brain barrier. Indian J Pharmacol  2004,36(3),140-147","journal-title":"Indian J Pharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"118813","DOI":"10.1016\/j.ijpharm.2019.118813","volume":"572","author":"Mato L.Y.","year":"2019","unstructured":"Mato L.Y.; Nasal route for vaccine and drug delivery: Features and current opportunities. Int J Pharm  2019,572,118813","journal-title":"Int J Pharm"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.bcp.2011.10.014","volume":"83","author":"McGonigle P.","year":"2012","unstructured":"McGonigle P.; Peptide therapeutics for CNS indications. Biochem Pharmacol  2012,83(5),559-566","journal-title":"Biochem Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1021\/acs.molpharmaceut.2c00523","volume":"19","author":"Parrasia S.","year":"2022","unstructured":"Parrasia S.; Szab\u00f2 I.; Zoratti M.; Biasutto L.; Peptides as pharmacological carriers to the brain: Promises, shortcomings and challenges. Mol Pharm  2022,19(11),3700-3729","journal-title":"Mol Pharm"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1124\/jpet.119.258152","volume":"370","author":"Wang Z.","year":"2019","unstructured":"Wang Z.; Xiong G.; Tsang W.C.; Sch\u00e4tzlein A.G.; Uchegbu I.F.; Nose-to-brain delivery. J Pharmacol Exp Ther  2019,370(3),593-601","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1517\/17425247.2012.636801","volume":"9","author":"Bahadur S.","year":"2012","unstructured":"Bahadur S.; Pathak K.; Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opin Drug Deliv  2012,9(1),19-31","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"618360","DOI":"10.3389\/fnmol.2021.618360","volume":"14","author":"Belur L.R.","year":"2021","unstructured":"Belur L.R.; Romero M.; Lee J.; Pedersen P.K.M.; Nan Z.; Riedl M.S.; Vulchanova L.; Kitto K.F.; Fairbanks C.A.; Kozarsky K.F.; Orchard P.J.; Frey W.H.; Low W.C.; McIvor R.S.; Comparative effectiveness of intracerebroventricular, intrathecal, and intranasal routes of AAV9 vector administration for genetic therapy of neurologic disease in murine mucopolysaccharidosis type I. Front Mol Neurosci  2021,14,618360","journal-title":"Front Mol Neurosci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1002\/jps.20694","volume":"95","author":"Rabinowitz J.D.","year":"2006","unstructured":"Rabinowitz J.D.; Lloyd P.M.; Munzar P.; Myers D.J.; Cross S.; Damani R.; Quintana R.; Spyker D.A.; Soni P.; Cassella J.V.; Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. J Pharm Sci  2006,95(11),2438-2451","journal-title":"J Pharm Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/10717544.2019.1618419","volume":"26","author":"Abdou E.M.","year":"2019","unstructured":"Abdou E.M.; Kandil S.M.; Morsi A.; Sleem M.W.; In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. Drug Deliv  2019,26(1),689-699","journal-title":"Drug Deliv"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/ane.12107","volume":"128","author":"Grosset K.A.","year":"2013","unstructured":"Grosset K.A.; Malek N.; Morgan F.; Grosset D.G.; Inhaled dry powder apomorphine (VR040) for \u2018off \u2019 periods in Parkinson\u2019s disease: an in-clinic double-blind dose ranging study. Acta Neurol Scand  2013,128(3),166-171","journal-title":"Acta Neurol Scand"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1177\/1060028016659077","volume":"50","author":"Thompson J.P.","year":"2016","unstructured":"Thompson J.P.; Thompson D.F.; Nebulized fentanyl in acute pain. Ann Pharmacother  2016,50(10),882-891","journal-title":"Ann Pharmacother"},{"key":"ref=44","first-page":"439","volume":"10","author":"Trevino J.T.","year":"2020","unstructured":"Trevino J.T.; Quispe R.C.; Khan F.; Novak V.; Non-invasive strategies for nose-to-brain drug delivery. J Clin Trials  2020,10(7),439","journal-title":"J Clin Trials"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3390\/pharmaceutics13071088","volume":"13","author":"Bharadwaj V.N.","year":"2021","unstructured":"Bharadwaj V.N.; Tzabazis A.Z.; Klukinov M.; Manering N.A.; Yeomans D.C.; Intranasal administration for pain: Oxytocin and other polypeptides. Pharmaceutics  2021,13(7),1088","journal-title":"Pharmaceutics"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3390\/pharmaceutics12121230","volume":"12","author":"Bahadur S.","year":"2020","unstructured":"Bahadur S.; Pardhi D.M.; Rautio J.; Rosenholm J.M.; Pathak K.; Intranasal nanoemulsions for direct nose-to-brain delivery of actives for CNS disorders. Pharmaceutics  2020,12(12),1230","journal-title":"Pharmaceutics"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"626882","DOI":"10.3389\/fbioe.2020.626882","volume":"8","author":"Xu J.","year":"2020","unstructured":"Xu J.; Tao J.; Wang J.; Design and application in delivery system of intranasal antidepressants. Front Bioeng Biotechnol  2020,8,626882","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.3390\/pharmaceutics14091870","volume":"14","author":"Alabsi W.","year":"2022","unstructured":"Alabsi W.; Eedara B.B.; Basurto E.D.; Polt R.; Mansour H.M.; Nose-to-brain delivery of therapeutic peptides as nasal aerosols. Pharmaceutics  2022,14(9),1870","journal-title":"Pharmaceutics"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2165\/00126839-200708030-00001","volume":"8","author":"Merkus F.W.H.M.","year":"2007","unstructured":"Merkus F.W.H.M.; van den Berg M.P.; Can nasal drug delivery bypass the blood-brain barrier?: Questioning the direct transport theory. Drugs R D  2007,8(3),133-144","journal-title":"Drugs R D"},{"key":"ref=50","first-page":"45","author":"Cauna N.","year":"1982","unstructured":"Cauna N.; Blood and nerve supply of the nasal lining. The Nose: Upper Airway Physiology and the Atmospheric Environment  1982,45-69","journal-title":"The Nose: Upper Airway Physiology and the Atmospheric Environment"},{"key":"ref=51","first-page":"213","volume":"2","author":"DeSesso J.M.","year":"1993","unstructured":"DeSesso J.M.; The relevance to humans of animal models for inhalation studies of cancer in the nose and upper airways. Qual Assur  1993,2(3),213-231","journal-title":"Qual Assur"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.2174\/1381612827666210820100723","volume":"27","author":"Sharma M.","year":"2021","unstructured":"Sharma M.; Waghela S.; Mhatre R.; Saraogi G.K.; A recent update on intranasal delivery of high molecular weight proteins, peptides, and hormones. Curr Pharm Des  2021,27(42),4279-4299","journal-title":"Curr Pharm Des"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","volume":"88","author":"Fortuna A.","year":"2014","unstructured":"Fortuna A.; Alves G.; Serralheiro A.; Sousa J.; Falc\u00e3o A.; Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules. Eur J Pharm Biopharm  2014,88(1),8-27","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/pharmaceutics10030116","volume":"10","author":"G\u00e4nger S.","year":"2018","unstructured":"G\u00e4nger S.; Schindowski K.; Tailoring formulations for intranasal nose-to-brain delivery: A review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics  2018,10(3),116","journal-title":"Pharmaceutics"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2174\/1567201816666191029122740","volume":"16","author":"Kashyap K.","year":"2019","unstructured":"Kashyap K.; Shukla R.; Drug delivery and targeting to the brain through nasal route: Mechanisms, applications and challenges. Curr Drug Deliv  2019,16(10),887-901","journal-title":"Curr Drug Deliv"},{"key":"ref=56","first-page":"94","volume":"144","author":"Dey S.","year":"2011","unstructured":"Dey S.; Mahanti B.; Mazumder B.; Malgope A.; Dasgupta S.; Nasal drug delivery: An approach of drug delivery through nasal. Route Pharm Sin  2011,144,94-106","journal-title":"Route Pharm Sin"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.resp.2012.12.005","volume":"186","author":"Si X.A.","year":"2013","unstructured":"Si X.A.; Xi J.; Kim J.; Zhou Y.; Zhong H.; Modeling of release position and ventilation effects on olfactory aerosol drug delivery. Respir Physiol Neurobiol  2013,186(1),22-32","journal-title":"Respir Physiol Neurobiol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0378-5173(98)00367-6","volume":"178","author":"Soane R.J.","year":"1999","unstructured":"Soane R.J.; Frier M.; Perkins A.C.; Jones N.S.; Davis S.S.; Illum L.; Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm  1999,178(1),55-65","journal-title":"Int J Pharm"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0169-409X(97)00059-8","volume":"29","author":"Marttin E.","year":"1998","unstructured":"Marttin E.; Schipper N.G.M.; Verhoef J.C.; Merkus F.W.H.M.; Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev  1998,29(1-2),13-38","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/pharmaceutics13030385","volume":"13","author":"Trenkel M.","year":"2021","unstructured":"Trenkel M.; Scherlie\u00df R.; Nasal powder formulations: In-vitro characterisation of the impact of powders on nasal residence time and sensory effects. Pharmaceutics  2021,13(3),385","journal-title":"Pharmaceutics"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1016\/j.bmc.2017.11.001","volume":"26","author":"Samaridou E.","year":"2018","unstructured":"Samaridou E.; Alonso M.J.; Nose-to-brain peptide delivery \u2013 The potential of nanotechnology. Bioorg Med Chem  2018,26(10),2888-2905","journal-title":"Bioorg Med Chem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1089\/jam.2006.19.510","volume":"19","author":"Suman J.D.","year":"2006","unstructured":"Suman J.D.; Laube B.L.; Dalby R.; Validity of in vitro tests on aqueous spray pumps as surrogates for nasal deposition, absorption, and biologic response. J Aerosol Med  2006,19(4),510-521","journal-title":"J Aerosol Med"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/03639045.2020.1762202","volume":"46","author":"Li X.T.","year":"2020","unstructured":"Li X.T.; Su J.; Kamal Z.; Guo P.; Wu X.; Lu L.; Wu H.; Qiu M.; Odorranalectin modified PEG-PLGA\/PEG-PBLG curcumin-loaded nanoparticle for intranasal administration. Drug Dev Ind Pharm  2020,46(6),899-909","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1021\/mp400680d","volume":"11","author":"Lalatsa A.","year":"2014","unstructured":"Lalatsa A.; Schatzlein A.G.; Uchegbu I.F.; Strategies to deliver peptide drugs to the brain. Mol Pharm  2014,11(4),1081-1093","journal-title":"Mol Pharm"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1089\/jamp.2011.0924","volume":"25","author":"Djupesland P.G.","year":"2012","unstructured":"Djupesland P.G.; Skretting A.; Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv  2012,25(5),280-289","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jddst.2016.05.003","volume":"35","author":"Warnken Z.N.","year":"2016","unstructured":"Warnken Z.N.; Smyth H.D.C.; Watts A.B.; Weitman S.; Kuhn J.G.; Williams R.O.; Formulation and device design to increase nose to brain drug delivery. J Drug Deliv Sci Technol  2016,35,213-222","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.2174\/138920112803341752","volume":"13","author":"Misra A.","year":"2012","unstructured":"Misra A.; Kher G.; Drug delivery systems from nose to brain. Curr Pharm Biotechnol  2012,13(12),2355-2379","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/pharmaceutics13122049","volume":"13","author":"Lee D.","year":"2021","unstructured":"Lee D.; Minko T.; Nanotherapeutics for nose-to-brain drug delivery: An approach to bypass the blood brain barrier. Pharmaceutics  2021,13(12),2049","journal-title":"Pharmaceutics"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14712598.3.1.45","volume":"3","author":"Duvvuri S.","year":"2003","unstructured":"Duvvuri S.; Majumdar S.; Mitra A.K.; Drug delivery to the retina: Challenges and opportunities. Expert Opin Biol Ther  2003,3(1),45-56","journal-title":"Expert Opin Biol Ther"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","volume":"195","author":"Crowe T.P.","year":"2018","unstructured":"Crowe T.P.; Greenlee M.H.W.; Kanthasamy A.G.; Hsu W.H.; Mechanism of intranasal drug delivery directly to the brain. Life Sci  2018,195,44-52","journal-title":"Life Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jconrel.2014.05.003","volume":"190","author":"Casettari L.","year":"2014","unstructured":"Casettari L.; Illum L.; Chitosan in nasal delivery systems for therapeutic drugs. J Control Release  2014,190,189-200","journal-title":"J Control Release"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/1567201053586047","volume":"2","author":"Vyas T.","year":"2005","unstructured":"Vyas T.; Shahiwala A.; Marathe S.; Misra A.; Intranasal drug delivery for brain targeting. Curr Drug Deliv  2005,2(2),165-175","journal-title":"Curr Drug Deliv"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/jps.21924","volume":"99","author":"Dhuria S.V.","year":"2010","unstructured":"Dhuria S.V.; Hanson L.R.; Frey W.H.; Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci  2010,99(4),1654-1673","journal-title":"J Pharm Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","volume":"11","author":"Illum L.","year":"2000","unstructured":"Illum L.; Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci  2000,11(1),1-18","journal-title":"Eur J Pharm Sci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/pharmaceutics14030629","volume":"14","author":"Crowe T.P.","year":"2022","unstructured":"Crowe T.P.; Hsu W.H.; Evaluation of recent intranasal drug delivery systems to the central nervous system. Pharmaceutics  2022,14(3),629","journal-title":"Pharmaceutics"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuroscience.2008.01.013","volume":"152","author":"Thorne R.G.","year":"2008","unstructured":"Thorne R.G.; Hanson L.R.; Ross T.M.; Tung D.; Frey W.H.; Delivery of interferon-\u03b2 to the monkey nervous system following intranasal administration. Neuroscience  2008,152(3),785-797","journal-title":"Neuroscience"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/dom.13279","volume":"20","author":"Schmid V.","year":"2018","unstructured":"Schmid V.; Kullmann S.; Gfr\u00f6rer W.; Hund V.; Hallschmid M.; Lipp H.P.; H\u00e4ring H.U.; Preissl H.; Fritsche A.; Heni M.; Safety of intranasal human insulin: A review. Diabetes Obes Metab  2018,20(7),1563-1577","journal-title":"Diabetes Obes Metab"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/pharmaceutics13071079","volume":"13","author":"Maaz A.","year":"2021","unstructured":"Maaz A.; Blagbrough I.S.; De Bank P.A.; In vitro evaluation of nasal aerosol depositions: An insight for direct nose to brain drug delivery. Pharmaceutics  2021,13(7),1079","journal-title":"Pharmaceutics"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1113\/jphysiol.1983.sp014731","volume":"339","author":"Bradbury M.W.","year":"1983","unstructured":"Bradbury M.W.; Westrop R.J.; Factors influencing exit of substances from cerebrospinal fluid into deep cervical lymph of the rabbit. J Physiol  1983,339(1),519-534","journal-title":"J Physiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1743-8454-1-2","volume":"1","author":"Johnston M.","year":"2004","unstructured":"Johnston M.; Zakharov A.; Papaiconomou C.; Salmasi G.; Armstrong D.; Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res  2004,1(1),2","journal-title":"Cerebrospinal Fluid Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1365-2990.1993.tb00476.x","volume":"19","author":"Kida S.","year":"1993","unstructured":"Kida S.; Pantazis A.; Weller R.O.; CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol Appl Neurobiol  1993,19(6),480-488","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2990.2006.00737.x","volume":"32","author":"Walter B.A.","year":"2006","unstructured":"Walter B.A.; Valera V.A.; Takahashi S.; Ushiki T.; The olfactory route for cerebrospinal fluid drainage into the peripheral lymphatic system. Neuropathol Appl Neurobiol  2006,32(4),388-396","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=83","first-page":"64","volume":"5","author":"Dhanda D.S.","year":"2005","unstructured":"Dhanda D.S.; Frey W.H.; Leopold D.; Kompella U.B.; Approaches for drug deposition in the human olfactory epithelium. Drug Deliv Technol  2005,5,64-72","journal-title":"Drug Deliv Technol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nn0602-849","volume":"5","author":"Born J.","year":"2002","unstructured":"Born J.; Lange T.; Kern W.; McGregor G.P.; Bickel U.; Fehm H.L.; Sniffing neuropeptides: A transnasal approach to the human brain. Nat Neurosci  2002,5(6),514-516","journal-title":"Nat Neurosci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.2042-7158.1994.tb03817.x","volume":"46","author":"Sakane T.","year":"2011","unstructured":"Sakane T.; Akizuki M.; Yamashita S.; Sezaki H.; Nadai T.; Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: The relation to the dissociation of the drug. J Pharm Pharmacol  2011,46(5),378-379","journal-title":"J Pharm Pharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ijpharm.2007.03.041","volume":"341","author":"Wang Q.","year":"2007","unstructured":"Wang Q.; Chen G.; Zeng S.; Pharmacokinetics of Gastrodin in rat plasma and CSF after I.N. and I.V. Int J Pharm  2007,341(1-2),20-25","journal-title":"Int J Pharm"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"R869","DOI":"10.1152\/ajpregu.00173.2002","volume":"283","author":"Papaiconomou C.","year":"2002","unstructured":"Papaiconomou C.; Sosic B.R.; Zakharov A.; Johnston M.; Does neonatal cerebrospinal fluid absorption occur via arachnoid projections or extracranial lymphatics? Am J Physiol Regul Integr Comp Physiol  2002,283(4),R869-R876","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.mehy.2008.10.031","volume":"72","author":"Filippidis A.","year":"2009","unstructured":"Filippidis A.; Fountas K.N.; Nasal lymphatics as a novel invasion and dissemination route of bacterial meningitis. Med Hypotheses  2009,72(6),694-697","journal-title":"Med Hypotheses"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"850","DOI":"10.4187\/respcare.03537","volume":"60","author":"Corcoran T.E.","year":"2015","unstructured":"Corcoran T.E.; Imaging in aerosol medicine. Respir Care  2015,60(6),850-857","journal-title":"Respir Care"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/17425247.2020.1730807","volume":"17","author":"Ehrmann S.","year":"2020","unstructured":"Ehrmann S.; Schmid O.; Darquenne C.; Rothen-Rutishauser B.; Sznitman J.; Yang L.; Barosova H.; Vecellio L.; Mitchell J.; Heuze-Vourc\u2019h N.; Innovative preclinical models for pulmonary drug delivery research. Expert Opin Drug Deliv  2020,17(4),463-478","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1152\/japplphysiol.00146.2012","volume":"113","author":"Robertson H.T.","year":"2012","unstructured":"Robertson H.T.; Buxton R.B.; Imaging for lung physiology: What do we wish we could measure? J Appl Physiol  2012,113(2),317-327","journal-title":"J Appl Physiol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/9781118799536.ch2","author":"Fouras A.","year":"2015","unstructured":"Fouras A.; Dubsky S.; The role of functional lung imaging in the improvement of pulmonary drug delivery. Pulm Drug Deliv  2015,19-34","journal-title":"Pulm Drug Deliv"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1023\/A:1016258931856","volume":"12","author":"Wolf W.","year":"1995","unstructured":"Wolf W.; Imaging can be much more than pretty pictures. Pharm Res  1995,12(12),1821-1822","journal-title":"Pharm Res"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2165\/00003088-200241080-00003","volume":"41","author":"Fischman A.J.","year":"2002","unstructured":"Fischman A.J.; Alpert N.M.; Rubin R.H.; Pharmacokinetic imaging. Clin Pharmacokinet  2002,41(8),581-602","journal-title":"Clin Pharmacokinet"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1183\/13993003.01880-2015","volume":"47","author":"Locke L.W.","year":"2016","unstructured":"Locke L.W.; Myerburg M.M.; Weiner D.J.; Markovetz M.R.; Parker R.S.; Muthukrishnan A.; Weber L.; Czachowski M.R.; Lacy R.T.; Pilewski J.M.; Corcoran T.E.; Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung. Eur Respir J  2016,47(5),1392-1401","journal-title":"Eur Respir J"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.chest.2021.05.013","volume":"160","author":"Corcoran T.E.","year":"2021","unstructured":"Corcoran T.E.; Huber A.S.; Hill S.L.; Locke L.W.; Weber L.; Muthukrishnan A.; Heidrich E.M.; Wenzel S.; Myerburg M.M.; Mucociliary clearance differs in mild asthma by levels of type 2 inflammation. Chest  2021,160(5),1604-1613","journal-title":"Chest"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijpharm.2007.05.024","volume":"344","author":"Mougin-Degraef M.","year":"2007","unstructured":"Mougin-Degraef M.; Bourdeau C.; Jestin E.; Sa\u00ef-Maurel C.; Bourgeois M.; Sa\u00ebc P.R.L.; Th\u00e9drez P.; Gestin J.F.; Barbet J.; Chauvet F.A.; Doubly radiolabeled liposomes for pretargeted radioimmunotherapy. Int J Pharm  2007,344(1-2),110-117","journal-title":"Int J Pharm"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/S0140-6736(82)91269-7","volume":"320","author":"Wollmer P.","year":"1982","unstructured":"Wollmer P.; Pride N.B.; Rhodes C.G.; Sanders A.; Pike V.W.; Palmer A.J.; Silvester D.J.; Liss R.H.; Measurement of pulmonary erythromycin concentration in patients with lobar pneumonia by means of positron tomography. Lancet  1982,320(8312),1361-1364","journal-title":"Lancet"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s00259-009-1170-5","volume":"36","author":"Bajc M.","year":"2009","unstructured":"Bajc M.; Neilly J.B.; Miniati M.; Schuemichen C.; Meignan M.; Jonson B.; EANM guidelines for ventilation\/perfusion scintigraphy. Eur J Nucl Med Mol Imaging  2009,36(8),1356-1370","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"573","DOI":"10.4187\/respcare.07715","volume":"66","author":"McPeck M.","year":"2021","unstructured":"McPeck M.; Ashraf S.; Cuccia A.D.; Smaldone G.C.; Factors determining continuous infusion aerosol delivery during mechanical ventilation. Respir Care  2021,66(4),573-581","journal-title":"Respir Care"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/jamp.2018.1505","volume":"33","author":"Gregory T.J.","year":"2020","unstructured":"Gregory T.J.; Irshad H.; Chand R.; Kuehl P.J.; Deposition of aerosolized lucinactant in non-human primates. J Aerosol Med Pulm Drug Deliv  2020,33(1),21-33","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"105472","DOI":"10.1016\/j.ejps.2020.105472","volume":"153","author":"Israel S.","year":"2020","unstructured":"Israel S.; Kumar A.; DeAngelis K.; Aurivillius M.; Dorinsky P.; Roche N.; Usmani O.S.; Pulmonary deposition of budesonide\/glycopyrronium\/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects. Eur J Pharm Sci  2020,153,105472","journal-title":"Eur J Pharm Sci"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.rmed.2018.03.029","volume":"138","author":"Kappeler D.","year":"2018","unstructured":"Kappeler D.; Sommerer K.; Kietzig C.; Huber B.; Woodward J.; Lomax M.; Dalvi P.; Pulmonary deposition of fluticasone propionate\/formoterol in healthy volunteers, asthmatics and COPD patients with a novel breath-triggered. Inhaler Respir Med  2018,138,107-114","journal-title":"Inhaler Respir Med"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13244-011-0146-8","volume":"3","author":"Biederer J.","year":"2012","unstructured":"Biederer J.; Beer M.; Hirsch W.; Wild J.; Fabel M.; Puderbach M.; Van Beek E.J.R.; MRI of the lung (2\/3). Why \u2026 when \u2026 how? Insights Imaging  2012,3(4),355-371","journal-title":"Insights Imaging"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4137\/MRI.S23559","volume":"8","author":"Fox M.S.","year":"2015","unstructured":"Fox M.S.; Gaudet J.M.; Foster P.J.; Fluorine-19 mri contrast agents for cell tracking and lung imaging. Magn Reson Insights  2015,8(S1),53-67","journal-title":"Magn Reson Insights"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/17425247.2019.1597051","volume":"16","author":"Gholizadeh H.","year":"2019","unstructured":"Gholizadeh H.; Cheng S.; Pozzoli M.; Messerotti E.; Traini D.; Young P.; Kourmatzis A.; Ong H.X.; Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders. Expert Opin Drug Deliv  2019,16(4),453-466","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1208\/s12249-019-1517-6","volume":"20","author":"Gholizadeh H.","year":"2019","unstructured":"Gholizadeh H.; Messerotti E.; Pozzoli M.; Cheng S.; Traini D.; Young P.; Kourmatzis A.; Caramella C.; Ong H.X.; Application of a thermosensitive in situ gel of chitosan-based nasal spray loaded with tranexamic acid for localised treatment of nasal wounds. AAPS PharmSciTech  2019,20(7),299","journal-title":"AAPS PharmSciTech"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1007\/s11095-022-03388-7","volume":"39","author":"Chen J.Z.","year":"2022","unstructured":"Chen J.Z.; Finlay W.H.; Martin A.; In vitro regional deposition of nasal sprays in an idealized nasal inlet: Comparison with in vivo gamma scintigraphy. Pharm Res  2022,39(11),3021-3028","journal-title":"Pharm Res"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.3390\/pharmaceutics15061657","volume":"15","author":"Seifelnasr A.","year":"2023","unstructured":"Seifelnasr A.; Si X.A.; Xi J.; Visualization and estimation of nasal spray delivery to olfactory mucosa in an image-based transparent nasal model. Pharmaceutics  2023,15(6),1657","journal-title":"Pharmaceutics"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jconrel.2023.01.011","volume":"354","author":"Law L.H.","year":"2023","unstructured":"Law L.H.; Huang J.; Xiao P.; Liu Y.; Chen Z.; Lai J.H.C.; Han X.; Cheng G.W.Y.; Tse K.H.; Chan K.W.Y.; Multiple CEST contrast imaging of nose-to-brain drug delivery using iohexol liposomes at 3T MRI. J Control Release  2023,354,208-220","journal-title":"J Control Release"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1211\/0022357021778880","volume":"54","author":"Dan Y.","year":"2010","unstructured":"Dan Y.; Murakami H.; Koyabu N.; Ohtani H.; Sawada Y.; Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil. J Pharm Pharmacol  2010,54(5),729-733","journal-title":"J Pharm Pharmacol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/pharmaceutics14051026","volume":"14","author":"Mizutani A.","year":"2022","unstructured":"Mizutani A.; Kobayashi M.; Ohuchi M.; Sasaki K.; Muranaka Y.; Torikai Y.; Fukakusa S.; Suzuki C.; Nishii R.; Haruta S.; Magata Y.; Kawai K.; Indirect SPECT imaging evaluation for possible nose-to-brain drug delivery using a compound with poor blood\u2013brain barrier permeability in mice. Pharmaceutics  2022,14(5),1026","journal-title":"Pharmaceutics"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.brainresbull.2020.04.012","volume":"160","author":"Bors L.A.","year":"2020","unstructured":"Bors L.A.; Bajza \u00c1.; M\u00e1ndoki M.; Tasi B.J.; Cserey G.; Imre T.; Szab\u00f3 P.; Erd\u0151 F.; Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats. Brain Res Bull  2020,160,65-73","journal-title":"Brain Res Bull"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/MNM.0000000000000048","volume":"35","author":"P\u00e9pin A.","year":"2014","unstructured":"P\u00e9pin A.; Daouk J.; Bailly P.; Hapdey S.; Meyer M.E.; Management of respiratory motion in PET\/computed tomography. Nucl Med Commun  2014,35(2),113-122","journal-title":"Nucl Med Commun"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1053\/j.semnuclmed.2021.04.003","volume":"51","author":"Afaq A.","year":"2021","unstructured":"Afaq A.; Faul D.; Chebrolu V.V.; Wan S.; Hope T.A.; Haibach P.V.; Bomanji J.; Pitfalls on PET\/MRI. Semin Nucl Med  2021,51(5),529-539","journal-title":"Semin Nucl Med"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.acra.2018.12.007","volume":"26","author":"Torres L.","year":"2019","unstructured":"Torres L.; Kammerman J.; Hahn A.D.; Zha W.; Nagle S. K.; Johnson K.; Sandbo N.; Meyer K.; Schiebler M.; Fain S. B.; Structure-function imaging of lung disease using ultrashort echo time MRI. Acad Radiol  2019,26(3),431-441","journal-title":"Acad Radiol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1081-1206(10)61957-6","volume":"89","author":"Bachert C.","year":"2002","unstructured":"Bachert C.; El-Akkad T.; Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol  2002,89(3),292-297","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2500\/108854101778249258","volume":"22","author":"Storms W.W.","year":"2001","unstructured":"Storms W.W.; Introduction: Patient preference of inhaled nasal corticosteroids. Allergy Asthma Proc  2001,22(6),S1-S3","journal-title":"Allergy Asthma Proc"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.otohns.2003.10.007","volume":"130","author":"Benninger M.S.","year":"2004","unstructured":"Benninger M.S.; Hadley J.A.; Osguthorpe J.D.; Marple B.F.; Leopold D.A.; Derebery M J.; Hannley M.; Techniques of intranasal steroid use. Otolaryngol Head Neck Surg  2004,130(1),5-24","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s11095-011-0417-6","volume":"28","author":"Kundoor V.","year":"2011","unstructured":"Kundoor V.; Dalby R.N.; Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast. Pharm Res  2011,28(8),1895-1904","journal-title":"Pharm Res"},{"key":"ref=121","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-381105\/v1","author":"Khawaja U.A.","year":"2021","unstructured":"Khawaja U.A.; Rizvi S.A.; Gong B.; Yeung W.; Gonzalez S.M.A.; Ferrer G.; Development and patient experience evaluation of a gentle atomizer for nasal drug delivery. Research Square  2021","journal-title":"Research Square"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1111\/epi.15159","volume":"60","author":"Detyniecki K.","year":"2019","unstructured":"Detyniecki K.; Van Ess P.J.; Sequeira D.J.; Wheless J.W.; Meng T.C.; Pullman W.E.; Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters\u2014A randomized, double-blind, placebo-controlled trial. Epilepsia  2019,60(9),1797-1808","journal-title":"Epilepsia"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"108390","DOI":"10.1016\/j.yebeh.2021.108390","volume":"125","author":"Chhabra R.","year":"2021","unstructured":"Chhabra R.; Gupta R.; Gupta L.K.; Intranasal midazolam versus intravenous\/rectal benzodiazepines for acute seizure control in children: A systematic review and meta-analysis. Epilepsy Behav  2021,125,108390","journal-title":"Epilepsy Behav"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"108811","DOI":"10.1016\/j.yebeh.2022.108811","volume":"134","author":"Cramer J.A.","year":"2022","unstructured":"Cramer J.A.; Faught E.; Davis C.; Misra S.N.; Carrazana E.; Rabinowicz A.L.; Quality-of-life results in adults with epilepsy using diazepam nasal spray for seizure clusters from a long-term, open-label safety study. Epilepsy Behav  2022,134,108811","journal-title":"Epilepsy Behav"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2022.04.011","volume":"132","author":"Tarquinio D.","year":"2022","unstructured":"Tarquinio D.; Dlugos D.; Wheless J.W.; Desai J.; Carrazana E.; Rabinowicz A.L.; Safety of diazepam nasal spray in children and adolescents with epilepsy: Results from a long-term phase 3 safety study. Pediatr Neurol  2022,132,50-55","journal-title":"Pediatr Neurol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1017\/S0022215113001229","volume":"128","author":"Tan N.C.","year":"2014","unstructured":"Tan N.C.; Drilling A.J.; Jardeleza C.; Wormald P.J.; Is nasal steroid spray bottle contamination a potential issue in chronic rhinosinusitis? J Laryngol Otol  2014,128(S1),S28-S33","journal-title":"J Laryngol Otol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1177\/00034894211007222","volume":"130","author":"Ahsanuddin S.","year":"2021","unstructured":"Ahsanuddin S.; Povolotskiy R.; Tayyab R.; Nasser W.; Barinsky G.L.; Grube J.G.; Paskhover B.; Adverse events associated with intranasal sprays: An analysis of the food and drug administration database and literature review. Ann Otol Rhinol Laryngol  2021,130(11),1292-1301","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40263-022-00930-4","volume":"36","author":"Lofts A.","year":"2022","unstructured":"Lofts A.; Abu-Hijleh F.; Rigg N.; Mishra R.K.; Hoare T.; Using the intranasal route to administer drugs to treat neurological and psychiatric illnesses: Rationale, successes, and future needs. CNS Drugs  2022,36(7),739-770","journal-title":"CNS Drugs"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"13383","DOI":"10.3390\/ijms232113383","volume":"23","author":"Di Scala C.","year":"2022","unstructured":"Di Scala C.; Armstrong N.; Chahinian H.; Chabri\u00e8re E.; Fantini J.; Yahi N.; AmyP53, a therapeutic peptide candidate for the treatment of Alzheimer\u2019s and Parkinson\u2019s disease: Safety, stability, pharmacokinetics parameters and nose-to brain delivery. Int J Mol Sci  2022,23(21),13383","journal-title":"Int J Mol Sci"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.trci.2018.06.012","volume":"4","author":"Umeda T.","year":"2018","unstructured":"Umeda T.; Tanaka A.; Sakai A.; Yamamoto A.; Sakane T.; Tomiyama T.; Intranasal rifampicin for Alzheimer\u2019s disease prevention. Alzheimers Dement  2018,4(1),304-313","journal-title":"Alzheimers Dement"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1124\/dmd.111.040782","volume":"39","author":"Stevens J.","year":"2011","unstructured":"Stevens J.; Ploeger B.A.; van der Graaf P.H.; Danhof M.; de Lange E.C.M.; Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab Dispos  2011,39(12),2275-2282","journal-title":"Drug Metab Dispos"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","volume":"281","author":"Agrawal M.","year":"2018","unstructured":"Agrawal M.; Saraf S.; Saraf S.; Antimisiaris S.G.; Chougule M.B.; Shoyele S.A.; Alexander A.; Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release  2018,281,139-177","journal-title":"J Control Release"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"594","DOI":"10.2174\/1381612826666200115101544","volume":"26","author":"Bicker J.","year":"2020","unstructured":"Bicker J.; Fortuna A.; Alves G.; Falc\u00e3o A.; Nose-to-brain delivery of natural compounds for the treatment of central nervous system disorders. Curr Pharm Des  2020,26(5),594-619","journal-title":"Curr Pharm Des"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/S0140-6736(19)32096-3","volume":"394","author":"Siskind D.","year":"2019","unstructured":"Siskind D.; Kisely S.; Balancing body and mind: Selecting the optimal antipsychotic. Lancet  2019,394(10202),900-902","journal-title":"Lancet"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/10717544.2013.838713","volume":"21","author":"Mittal D.","year":"2014","unstructured":"Mittal D.; Ali A.; Md S.; Baboota S.; Sahni J.K.; Ali J.; Insights into direct nose to brain delivery: Current status and future perspective. Drug Deliv  2014,21(2),75-86","journal-title":"Drug Deliv"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"709","DOI":"10.4155\/tde.14.41","volume":"5","author":"Djupesland P.G.","year":"2014","unstructured":"Djupesland P.G.; Messina J.C.; Mahmoud R.A.; The nasal approach to delivering treatment for brain diseases: An anatomic, physiologic, and delivery technology overview. Ther Deliv  2014,5(6),709-733","journal-title":"Ther Deliv"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ijbiomac.2018.01.121","volume":"110","author":"Jawahar N.","year":"2018","unstructured":"Jawahar N.; Hingarh P.K.; Arun R.; Selvaraj J.; Anbarasan A.; S S.; G N.; Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers. Int J Biol Macromol  2018,110,269-275","journal-title":"Int J Biol Macromol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","volume":"379","author":"Mistry A.","year":"2009","unstructured":"Mistry A.; Stolnik S.; Illum L.; Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm  2009,379(1),146-157","journal-title":"Int J Pharm"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.2174\/0929867321666140716103130","volume":"21","author":"Ong W.Y.","year":"2014","unstructured":"Ong W.Y.; Shalini S.M.; Costantino L.; Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders. Curr Med Chem  2014,21(37),4247-4256","journal-title":"Curr Med Chem"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.3762\/bjnano.5.188","volume":"5","author":"Bantz C.","year":"2014","unstructured":"Bantz C.; Koshkina O.; Lang T.; Galla H.J.; Kirkpatrick C.J.; Stauber R.H.; Maskos M.; The surface properties of nanoparticles determine the agglomeration state and the size of the particles under physiological conditions. Beilstein J Nanotechnol  2014,5(1),1774-1786","journal-title":"Beilstein J Nanotechnol"},{"key":"ref=141","first-page":"1","volume":"4","author":"Putheti R.","year":"2009","unstructured":"Putheti R.; Patil M.C.; Obire O.; Nasal drug delivery in pharmaceutical and biotechnology: Present and future. J Sci Technol  2009,4,1-21","journal-title":"J Sci Technol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1517\/17425247.5.10.1159","volume":"5","author":"Wu H.","year":"2008","unstructured":"Wu H.; Hu K.; Jiang X.; From nose to brain: Understanding transport capacity and transport rate of drugs. Expert Opin Drug Deliv  2008,5(10),1159-1168","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jconrel.2005.09.047","volume":"110","author":"Matsuyama T.","year":"2016","unstructured":"Matsuyama T.; Morita T.; Horikiri Y.; Yamahara H.; Yoshino H.; Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant. J Control Release  2016,110(2),347-352","journal-title":"J Control Release"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3109\/10717544.2013.878857","volume":"22","author":"Shah B.M.","year":"2015","unstructured":"Shah B.M.; Misra M.; Shishoo C.J.; Padh H.; Nose to brain microemulsion-based drug delivery system of rivastigmine: Formulation and ex-vivo characterization. Drug Deliv  2015,22(7),918-930","journal-title":"Drug Deliv"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijpharm.2016.07.002","volume":"514","author":"Colombo G.","year":"2016","unstructured":"Colombo G.; Bortolotti F.; Chiapponi V.; Buttini F.; Sonvico F.; Invernizzi R.; Quaglia F.; Danesino C.; Pagella F.; Russo P.; Bettini R.; Colombo P.; Rossi A.; Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia. Int J Pharm  2016,514(1),229-237","journal-title":"Int J Pharm"},{"key":"ref=148a","first-page":"105","volume":"71","author":"Emirzeoglu M.","year":"2012","unstructured":"Emirzeoglu M.; Sahin B.; Celebi M.; Uzun A.; Bilgic S.; Tontus H.O.; Estimation of nasal cavity and conchae volumes by stereological method. Folia Morphol  2012,71(2),105-108","journal-title":"Folia Morphol"},{"key":"ref=148b","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4103\/0973-8398.45032","volume":"2","author":"Bhise S. B.","year":"2008","unstructured":"Bhise S. B.; Yadav A. V.; Avachat A. M.; Malayandi R.; Bioavailability of intranasal drug delivery system. Asian J Pharm  2008,2(4),201-215","journal-title":"Asian J Pharm"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","volume":"9","author":"Hanson L.R.","year":"2008","unstructured":"Hanson L.R.; Frey W.H.; Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci  2008,9(S3),S5","journal-title":"BMC Neurosci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1208\/s12249-014-0177-9","volume":"15","author":"Paliwal R.","year":"2014","unstructured":"Paliwal R.; Babu R.J.; Palakurthi S.; Nanomedicine scale-up technologies: Feasibilities and challenges. AAPS PharmSciTech  2014,15(6),1527-1534","journal-title":"AAPS PharmSciTech"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/ptr.6571","volume":"34","author":"Asadi S.","year":"2020","unstructured":"Asadi S.; Gholami M.S.; Siassi F.; Qorbani M.; Sotoudeh G.; Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial. Phytother Res  2020,34(4),896-903","journal-title":"Phytother Res"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","volume":"33","author":"Bobo D.","year":"2016","unstructured":"Bobo D.; Robinson K.J.; Islam J.; Thurecht K.J.; Corrie S.R.; Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm Res  2016,33(10),2373-2387","journal-title":"Pharm Res"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018285350240227073607","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/227676\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018285350240227073607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T04:48:59Z","timestamp":1752122939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/227676\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":151,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115672018285350240227073607","relation":{},"ISSN":["1567-2018"],"issn-type":[{"type":"print","value":"1567-2018"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}